UBS reiterates Buy on Rentokil Initial stock, keeps £5.40 target By Investing.com

Rentokil reported H2 2025 revenue of $6.9 billion and UBS reiterated a Buy with a £5.40 price target; the stock trades at $32.85 near a 52-week high of $33.47 after a 66% year gain. The company showed profitability improvements but posted a slight EPS miss, while InvestingPro flags the stock as overvalued on fair-value metrics. Rothschild Redburn upgraded the stock from Sell to Neutral and raised its target to GBP4.70 (from GBP4.20). UBS noted a strategic pivot in North American pest control that could boost volumes but cautioned about potential higher-cost investments following the new CEO appointment on March 16.

Analysis

Broadcom’s (AVGO) multi-year AI and networking supply commitments to hyperscalers shift its revenue mix from one-off SKU cycles to longer-duration, higher-visibility contracts; that structural change amplifies pricing power for high-density switching and optical modules and pulls forward utilization at TSMC and optical-component suppliers over the next 6–24 months. Second-order winners include high-margin software/firmware services tied to integrated systems (drive recurring engineering revenues), while legacy ASIC competitors face accelerated feature-bundling pressure that could compress their renewal pricing within 12–18 months.

For Google (GOOGL/GOOG) the strategic benefit is less about absolute margin today and more about optionality — owning long-term networking capacity reduces hyperscaler spot-market exposure and gives Google leverage to tune its stack away from single-vendor accelerator dependency. The flip side: longer contracts embed vendor concentration risk and create a visible target for regulator or counterparty negotiation on renewal economics; watch annual contract anniversary windows as 3–12 month catalysts.

Rentokil’s repositioning in North America increases the probability of stabilizing volumes but materially raises near-term capex and OPEX lines, creating a 6–18 month earnings hangover risk if ROI timing slips. Market consensus appears to prize defensive revenue stability over execution risk; a modest miss in conversion or higher-than-expected one-time spend will re-price multiple contraction quickly given current valuation.

Key tail-risks across both stories are hyperscaler re-negotiation (months) and execution slippage on capex/hiring (quarters); monitor Broadcom bookings cadence and Rentokil’s US contract gross margins as first-order reversal signals.

Key Decisions for Investors

• Long AVGO 6–12 month call spread (buy a nearer-term call, sell a higher strike) to capture 15–30% upside if AI/networking revenue inflects; limit max loss to premium (capped downside) and take profits on a 20–30% move above entry or on better-than-expected guidance cadence.
• Long GOOGL outright for 3–9 months to play reduced hyperscaler SKU risk and cloud optionality; hedge 25–50% of position by selling a 6–9 month out-of-the-money call to improve entry if modest upside and capex concerns persist (R:R ~2:1 assuming 20% upside vs 10% downside exposure).
• Short RTO (or buy RTO puts) 3–9 months to express valuation vulnerability versus operational risk — target a put buy to limit downside to premium with profit if shares fall 20% on higher-than-expected investment costs or weak conversion; set tight stop if company reports clear ROI acceleration.
• Pair trade: long AVGO / short RTO sized equally by notional for 6–12 months to capture asymmetric exposure to durable AI-driven tech spend versus cyclical/operational execution risk in services — this reduces broad market beta while amplifying idiosyncratic thesis (expect relative outperformance if AVGO up 15% and RTO down 10% over the next 6–12 months).